Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective

Table 1

Ongoing trials with targeted agents.

	Products	Trial
1	CDDP-Paclitaxel versus Topotecan-Paclitaxel ± bevacizumab	GOG 204
2	Poly tki (pazopanib) versus EGFR/HER2 dual inhibitor (lapatinib)	VEG 105281
3	VEGF and FGF2 inhibitor: Brivanib	227G
4	EGFR inhibitor erlotinib	GOG 227 D
5	EGFR-targeted antibody cetuximab	GOG 227 E
6	EGFR inhibition by cetuximab + CDDP	GOG 76DD
7	Vaccine: listeriolysin O E7 fusion peptide: ADXS11:	GOG 285
8	G1 checkpoint modulation, MK1775*, inhibitor of Wee1 kinase activity	GOG 265
9	Treatment with oncolytic viruses: PV701**	PV701
10	Farletuzumab and folate receptor antibody coupled to vinca drug***

*Inhibitor of Wee 1 kinase activity promotes apoptosis when p53 is null.
**Targets defect in interferon pathway (pathway disabled by HPV E6 and E7).
***Folate receptor expressed in 1/3 of (most aggressive) cervical cancers.